Viridian Therapeutics, Inc. (VRDN) Tops Q3 EPS by 16c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q3 EPS of ($1.09), $0.16 better than the analyst estimate of ($1.25). Revenue for the quarter came in at $72 thousand versus the consensus estimate of $141.08 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Lynx Equity sees Micron and SanDisk breakout as volatility normalizes
• Change in Nonfarm Payrolls (Aug) 162K vs 55K Expected, Unemployment Rate 4.1%